RxDoctor Payments DataLook up a doctor →

Joel Neutel, MD

Internal Medicine · Tustin, CANPI 1730163965

Payments from drug & device makers

$34,877,046in general payments, 2019–2025

Across 1,592 payments — averaging $21,908 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$17M
  • Pfizer$10.4M
  • Eli Lilly$1.4M
  • Edwards Lifesciences$876K
  • Incyte Corporation$819K
  • Gilead$665K
  • plus $3.6M from 28 others
$14,862in research payments, 2019–2025

Across 5 payments — averaging $2972.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$15K
  • Amgen$291
  • Astellas Pharma Inc$66

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$34,877,046 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$17,501
Medicare patients
27
Services billed
102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Tustin

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →